Hormone receptor-positive breast cancer (luminal A and B)

Exam relevance: in 14 of more than 150 board exam reports · rank 55

Specialty
Gynaecology · Breast
Images
Histology & cytology 2
Exam relevance
14 of more than 150 reports · rank 55
Last updated
10/2026 · Dr. Pascal Bafteh
Contents
  1. Images (2)
  2. Definition
  3. Classification
  4. Occurrence & epidemiology
  5. Aetiopathogenesis
  6. Clinical features
  7. Diagnosis
  8. Treatment principles
  9. Keep learning in the app
  10. Further reading (selection)
  11. Cross-references

Images (2)

Hormone receptor-positive breast cancer (luminal A and B) – histology/cytology: Estrogen receptor immunohistochemistry: strong nuclear staining of nearly all tumour cells of a metastatic breast carcinoma (pleura) – hormone receptor positiveHistology & cytology
Estrogen receptor immunohistochemistry: strong nuclear staining of nearly all tumour cells of a metastatic breast carcinoma (pleura) – hormone receptor positiveImage: Yale Rosen from USA, “Metastatic breast carcinoma; pleura-Estrogen receptor Case 166 (5477628458)” (Wikimedia Commons) · CC BY-SA 2.0 · Source
Hormone receptor-positive breast cancer (luminal A and B) – histology/cytology: Progesterone receptor immunohistochemistry: diffuse strong nuclear staining of the tumour cells of the same metastatic breast carcinoma (pleura)Histology & cytology
Progesterone receptor immunohistochemistry: diffuse strong nuclear staining of the tumour cells of the same metastatic breast carcinoma (pleura)Image: Yale Rosen from USA, “Metastatic breast carcinoma; pleura - Progesterone receptor Case 166 (5477030089)” (Wikimedia Commons) · CC BY-SA 2.0 · Source
1 / 2

Definition

  • Hormone receptor-positive breast cancer with oestrogen and/or progesterone receptors, corresponding to the luminal A and luminal B molecular subtypes.

Classification

  • Luminal A tumours are grade 1 or 2, oestrogen and progesterone receptor-positive, HER2-negative and have low Ki-67.
  • Luminal B tumours are oestrogen receptor positive, often have a high Ki-67 fraction and may be HER2 positive or negative.

Occurrence & epidemiology

Epidemiology

  • Most breast cancers are luminal A; about 70% are hormone receptor-positive and HER2-negative.
  • Most oestrogen receptor-positive tumours are also progesterone receptor-positive; overall, about 70% of all breast cancers are progesterone receptor-positive.

Aetiopathogenesis

Aetiology and pathogenesis

  • Oestrogen and progesterone receptors are nuclear hormone receptors that promote DNA replication and cell division when their hormones bind, so oestrogen and progesterone can fuel tumour growth.
  • Early menarche, late menopause and older age at first pregnancy increase breast cancer risk.

Clinical features

  • Luminal A and B tumours generally grow more slowly than HER2-enriched and triple-negative (basal-like) tumours.

Diagnosis

  • Breast cancers are usually tested for oestrogen and progesterone receptors and HER2, often also for the Ki-67 protein.
  • Most guidelines regard immunohistochemical staining of 1% or more as oestrogen receptor-positive; ER-low tumours with 1–10% expression (about 2–7% of cases) resemble oestrogen receptor-negative tumours at the molecular level.
  • Ki-67 is found only in dividing cells, and a high proportion of Ki-67-positive tumour cells indicates rapid division.
  • Hormone receptor status can change over time.

Treatment principles

  • Local treatment consists of breast-conserving surgery with radiotherapy or mastectomy, together with axillary staging.
  • The cornerstone is endocrine therapy over several years with anti-oestrogens or aromatase inhibitors, combined with ovarian function suppression in high-risk premenopausal patients where appropriate.
  • Whether additional chemotherapy or targeted agents are needed depends on the recurrence risk, which is usually lower in luminal A than in luminal B tumours; the decision is made by the tumour board.

Specific treatment regimens with drugs and doses are covered in the GynFuchs app.

Keep learning in the app

In the GynFuchs app you can learn Hormone receptor-positive breast cancer (luminal A and B) with flashcards, exam questions and image tasks (colposcopy, ultrasound, CTG) – free, in your browser or as an app.

Open in browser  About GynFuchs →

Further reading (selection)

  1. National Cancer Institute: Breast Cancer Biomarkers
  2. MSD Manual Professional: Breast Cancer
  3. Clinical implication of low estrogen receptor (ER-low) expression in breast cancer

Cross-references

Keep learning

Keep learning with flashcards, exam questions and spot diagnoses in the GynFuchs app – free, in your browser or as an app.

Related pages: Inflammatory breast cancer · Intraductal papilloma · Lobular breast cancer and lobular neoplasia

Note: Learning content from the GynFuchs app (flashcards, exam questions, image cases) for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.